Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

  • End date
    Jun 5, 2024
  • participants needed
  • sponsor
    Mitsubishi Tanabe Pharma Development America, Inc.
Updated on 5 May 2022


To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS), based on the time from the randomization date in Study MT-1186-A02 to at least a 12-point decrease in Revised ALS Functional Rating Score (ALSFRS-R) or death, whichever happens first, over the course of the study or until oral edaravone is commercially available in that country

Condition ALS
Treatment Placebo, MT-1186
Clinical Study IdentifierNCT05151471
SponsorMitsubishi Tanabe Pharma Development America, Inc.
Last Modified on5 May 2022


Yes No Not Sure

Inclusion Criteria

Subjects must provide a signed and dated informed consent form to participate in the study
Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study
Subjects must be willing to cooperate and comply with all protocol restrictions and requirements
Subjects must have successfully completed all Study MT-1186-A02 visits and have been compliant with study drug

Exclusion Criteria

Subjects of childbearing potential unwilling to use an acceptable method of contraception from the Day 1/screening visit until 3 months after the last dose of study medication. Subjects who are sexually active who do not agree to use contraception during the study period
Subjects who are female, of childbearing potential, and pregnant (a positive pregnancy test) or lactating at the Day 1/screening visit
Subjects who have a significant risk of suicide. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) at Week 48 of Study MT-1186-A02
Subjects who are not eligible to continue in the study, as judged by the Investigator in conjunction with the MTDA medical monitor
Subjects who are unable to take their medications orally or through a PEG/RIG tube
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note